Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Jefferies Assumes Taysha Gene Therapies (TSHA) at Buy, Raises PT to $45
May 11, 2021 7:56 AM EDTJefferies analyst Eun Yang assumes coverage on Taysha Gene Therapies (NASDAQ: TSHA) with a Buy rating and a price target of $45.00 (from $34.00).
The analyst commented, "Building upon the management experience with AAV9-based gene therapy (Zolgensma),TSHA has an extensive pipeline for CNS... More
Taysha Gene Therapies (TSHA) Misses Q1 EPS by 31c
May 11, 2021 7:12 AM EDTTaysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($0.87), $0.31 worse than the analyst estimate of ($0.56).
Our team has ushered in the new year with a continued focus on achieving our corporate objectives and creating value for patients and shareholders, said RA Session II, President, Founder and CEO of Taysha. Our recent acquisition of TSHA-120 for GAN immediately transformed Taysha into a pivotal-stage gene therapy company. Based on the compelling clinical and preclinical data package generated to date for this promising product candidate, we intend to engage with regulatory agencies to discuss a pathway to... More
